Treating acute myeloid leukemia in older adults

Size: px
Start display at page:

Download "Treating acute myeloid leukemia in older adults"

Transcription

1 ACUTE MYELOID LEUKEMIA IN THE ELDERLY PATIENT Treating acute myeloid leukemia in older adults Eunice S. Wang 1 1 Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY Acute myeloid leukemia (AML) is a disease of older adults, with a median age of 67 years at presentation. In the past, only a third of older patients (defined as individuals older than years of age) with AML received definitive therapy for their disease due to concerns about their overall fitness and potential treatment-related mortality. However, compelling epidemiological data have shown unequivocally that older AML patients up to 80 years old both tolerate and survive longer after therapy than their untreated counterparts. Current therapeutic options for elderly individuals with AML include intensive chemotherapy with a cytarabine and anthracycline backbone, hypomethylating agents (decitabine and azacitidine), low-dose cytarabine, investigational agents, and supportive care with hydroxyurea and transfusions. Over the last few years, there has been increasing debate regarding the appropriate therapeutic approach to take in older adults given the diversity of the geriatric patient population and heterogeneous AML disease biology. This article discusses how performance status, comorbidities, disease characteristics, quality of life concerns, and long-term treatment goals affect the selection of appropriate therapy for older adults with AML. Risks and benefits of each treatment approach based on the most recent medical literature are discussed. Finally, a treatment algorithm summarizing these data and incorporating geriatric assessment and molecular and cytogenetic markers predictive of therapeutic response is proposed to aid in the clinical decision-making process. Learning Objective To identify appropriate therapeutic strategies for the older patient with AML, taking into consideration the patient s performance status, comorbidities, disease characteristics, and goals Background Acute myeloid leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years. In 2014, an estimated new cases of AML are expected in the United States, with deaths from this disease. 1 The incidence of AML appears to be increasing, in part due to the overall aging population, toxic exposures, and the prior use of chemotherapy and/or radiation for the treatment of other malignancies. Ironically, increased cure rates in other cancer types due to earlier disease detection and more effective therapies are leading to growing numbers of individuals at risk for the development of therapy-related myelodysplastic syndrome and AML (t-mds/aml). In general, adults 60 years old with AML fare poorly compared with younger patients, with overall 5-year survival rates as low as 5%-10%. Although age is an important adverse prognostic factor for AML outcomes, a myriad of other biological and clinical factors are largely responsible for the poor outcomes. AML in the elderly exhibits several biological features associated with chemoresistance, including a higher incidence of unfavorable cytogenetic findings (monosomy 7, del (5q), complex karyotypes), frequent involvement of a more immature leukemic precursor clone, multidrug resistance mediated by MDR1/ P-glycoprotein, and the presence of antecedent hematopoietic disorders. 2 Older patients with AML are also more likely to have more numerous and severe comorbidities, contributing to more frequent treatment-related morbidity and mortality. 3,4 Given these complexities, treatment of elderly patients with AML remains highly challenging and controversial. Individuals up to the age of 80 years benefit from AML therapy Since the 1970s, the standard initial therapy for patients with AML has consisted of intensive chemotherapy with 7 days of continuous infusional cytarabine and 3 days of an anthracycline drug (the so-called 7 3 regimen). In the past, however, many clinicians would not offer chemotherapy to the majority of individuals 60 years old because of the fear of treatmentrelated morbidity/mortality in patients with multiple other comorbidities. In fact, the opposite is true. Recent studies have consistently demonstrated that early death rates in patients with AML are higher in untreated than in treated individuals. In 2009, Juliusson et al presented data from the Swedish Acute Leukemia Registry ( ) demonstrating that early death rates in patients of all ages with AML were consistently lower after intensive rather than palliative therapy. 5 Importantly, they also showed that the poor initial performance status of older patients with AML did not necessarily preclude achievement of longterm survival after therapy and that individuals up to the age of 80 years both tolerated intensive induction treatment and survived longer compared with those managed with palliative care alone. 5 Oran and Weisdorf found similar results in an analysis of Surveillance Epidemiology and End Results (SEER) and Medicare claims data from 5480 older patients diagnosed with AML in the United States. 6 Once again, older patients (median age 78 years) receiving AML treatment demonstrated longer overall survival (median 6 vs 2 months, p.01) compared with untreated patients. The most significant differences between clinical outcomes in treated versus untreated patients were noted in individuals between the ages of 65 and 69 years (10 vs 4 months, p.01) and years of age (8 vs 3 months, p.01). 6 Based on these data, definitive therapy should be offered routinely to all older individuals with AML as the most effective means of prolonging overall survival. 14 American Society of Hematology

2 When to initiate induction therapy for the older patient with AML Selection of the appropriate therapeutic approach for the older AML patient should be individualized based on patient-specific factors (ie, his/her fitness for chemotherapy, as discussed in a separate chapter by Dr. Klepin) and biological markers of disease predictive of response to various therapeutic interventions. Any critically ill patients with rapidly progressive AML disease (such as those with hyperleukocytosis with a WBC count / L) and/or evidence of respiratory, neurologic, or other organ compromise should undergo immediate therapy with hydroxyurea and leukapheresis, followed by cytotoxic chemotherapy. Aside from these specific patients, there appears to be no benefit to early initiation of therapy (ie, within hours of diagnosis) in the majority of older patients with AML. 7 In fact, delaying therapy initiation to obtain further information on an individual patient s disease cytogenetic results (and possibly mutational status) may improve individual outcomes by allowing for the appropriate selection of a treatment approach most likely to result in remission and/or prolonged survival in that particular individual. Selection of the appropriate upfront therapy for older AML patients Intensive induction chemotherapy Intensive induction chemotherapy using a cytarabine and anthracycline backbone is considered by most to be the most effective upfront AML therapy. A review of the published literature on AML treatment between 1989 and 2006 confirmed that the median overall survival of older patients (median age 70 years) with AML treated with intensive induction therapy was significantly longer (30 weeks) than patients treated with low-intensity therapy (12 weeks) or best supportive care. 8 In younger patients with AML, it is well established that disease karyotype constitutes the single most important independent predictor of response to intensive chemotherapy. Recently, there have been a multitude of studies analyzing the clinical outcomes of older ( years of age) patients with AML treated with intensive therapy in an attempt to identify factors predictive of response in the geriatric patient population. Investigators at the M.D. Anderson Cancer Center analyzed data on 998 older patients aged 65 and older receiving intensive chemotherapy at their institution. They reported significant heterogeneity in outcomes among geriatric patients with AML and identified 7 factors (age, performance status, karyotype, treatment outside of a laminar flow room, lactate dehydrogenase level, creatinine 1.3, and presence of antecedent hematological disease) that were correlated with clinical response. 4 Depending on the prognostic model, geriatric patients had overall complete remission (CR) rates ranging from 20% to 50%, induction mortality ranging from 10% to 50% (average 29%-36%), and 1-year survival rates of 10%-50%. 4,9 Although these investigators listed age 75 years and poor performance status as negative prognostic factors, other groups have argued that these factors are not as important in predicting outcome as underlying disease biology and other clinical factors. 10,11 At present, the one factor most consistently aligning with clinical outcome after intensive chemotherapy remains karyotype. 4,10,11 Older patients with AML characterized by favorable- or intermediate-risk (nonadverse) karyotype have CR rates up to 60% after cytarabine- and anthracyline-based therapy. In contrast, older patients with AML associated with adverse karyotype have remission rates as low as 20%, with overall survival of 2-3 months. 4 Recent advances in our understanding of the diverse genetic and epigenetic aberrations underlying AML, and particularly cytogenetically normal karotype AML, in older adults demonstrate the potential for classifying future patients based on distinct biological profiles. 12 To date, however, the only molecularly defined subset of older patients with AML unequivocally benefiting from intensive chemotherapy are those harboring mutations in the nucleophosmin-1 (NPM-1) gene in the absence of mutations in the fms-like tyrosine kinase-3 (FLT-3). Why this gene mutation predicts for response to cytarabine- and anthracycline-based chemotherapy is not clear. However, in multiple studies, patients aged 60 years and greater with NPM-1-mutated AML have far superior outcomes and survival after intensive therapy compared with any other treatment modality The fact that, as of 2007, fewer than 5% of elderly patients with AML were tested for NPM-1 mutations at the time of diagnosis is another argument for the need for complete AML disease characterization before making any upfront treatment decisions in these individuals. 16 When considering intensive induction chemotherapy for older patients with AML, it is important to know what to expect with this treatment modality. Most studies have reported 8-week early mortality rates up to 20%-25% after intensive induction therapy. Despite very valid concerns about treatment-related mortality and morbidity, many fit older patients actually fare quite well with intensive therapy. Lowenberg et al demonstrated that patients between the ages of 60 and 65 years with AML both tolerated and benefited from increased daunorubicin dose (from 45 to 90 mg/m 2 ) similarly to younger patients. 17 As a result, clinical trials of intensive chemotherapy in older patients with AML now routinely use daunorubicin doses of at least 60 mg/m 2, with the recommendation that no dose reductions in anthracycline dose occur in individuals with normal left ventricular function. In the past, it was also commonly believed that older patients with AML frequently became so ill during induction therapy that they were admitted to the intensive care unit (ICU), with resultant high mortality rates. Jackson et al found that in fact only 9.4% of induction chemotherapy cycles resulted in ICU admission, with the predominant cause being infection, and that neither age, AML cytogenetic risk status, or type of chemotherapy (induction vs consolidation) predicted for ICU admission. 18 Although patients with AML admitted to the ICU had worse overall survival than those patients who were not, the chances of these patients surviving to hospital discharge and 12 months afterward were 59% and 41.3%, respectively. In fact, once these patients survived the acute event prompting ICU admission, they had similar overall survival rates as other AML patients undergoing chemotherapy. 18 Prioritization of quality of life (QOL) and preserving an older individual s activities of daily living are also cited as arguments against the use of intensive chemotherapy in geriatric cancer patients. As expected, older patients with AML may experience short-term declines in their overall QOL due to the need for inpatient hospitalization during the first 4 weeks of therapy. 19 However, surveys of mostly older patients with AML at 1, 1.5, 4, and 6 months after initiation of therapy demonstrated no significant adverse effects on multiple QOL parameters and no difference in their overall functional status after intensive chemotherapy. 19,20 Moreover, those patients achieving CR after intensive induction universally reported overall improvements in QOL and global, social, and emotional health 12 months after therapy. 21 What about patients above the age of 80 years? Investigators analyzing both the Swedish Leukemia Registry and the United States SEER database concluded that risks of intensive induction Hematology

3 chemotherapy were outweighed by treatment benefits only in patients with AML up to the age of 80 years. 56 We reviewed the outcomes of 92 octogenarian and nonagenarian patients with AML treated with intensive chemotherapy (n 59) or supportive care (n 33) at our institution. Intensive chemotherapy led to a CR rate of 26% and an improved median survival of 4.0 months. 22 Wetzler et al recently evaluated the outcomes of 90 very old patients (median age 82 years, range 80-89) with AML considered fit enough to be treated with intensive chemotherapy on cooperative group clinical trials. 23 They found an overall CR rate of 46%, median overall survival of 6 months, and a 1-year survival rate of 36%. Once again, AML with nonadverse karyotype and NPM-1 mutation were associated with improved clinical outcomes. 23 Although these data are obviously skewed by clinician bias in selecting fit older patients for clinical trial enrollment, consideration should be given to offering intensive chemotherapy to a select subset of patients 80 years and older for whom this modality might offer significant survival benefit. Low-dose cytarabine Low-dose cytarabine (also known as low-dose Ara-C or LDAC) has been used as a low-intensity therapeutic strategy for the treatment of elderly, unfit AML patients for several decades. Recent studies have highlighted the fact that even very small doses of cytarabine (typically given at 20 mg/m 2 administered once or twice daily for days per month) can induce CRs in 8%-18% of patients with AML and can prolong survival Although these results compare favorably with no remission after hydroxyurea and supportive care, LDAC is currently considered potentially inferior to other upfront therapies for older patients with AML, in part because no patients with AML with adverse cytogenetic findings achieve remission with this regimen. 24 Despite this fact, LDAC may still be a therapeutic option for geriatric patients with favorable or intermediate-risk karyotype AML whose medical issues (such as renal insufficiency) preclude the administration of intensive chemotherapy and who prefer to self-administer drug almost exclusively at home without the need for daily clinic visits or inpatient hospitalization. For some individuals, the convenience of this approach may outweigh the low remission rates. Because of the tolerability of LDAC, multiple clinical trials have explored combining LDAC with novel investigational agents in an attempt to improve responses in unfit older patients. Hypomethylating therapy Over the last several years, hypomethylating therapy with 1 of 2 agents, decitabine (Dec) and azacitidine (Aza), has been increasingly used in place of standard intensive chemotherapy for the treatment of unfit elderly patients with AML. A review of SEER data from 2005 to 2007 revealed that, after 2004, when these drugs became available to clinicians, the number of older AML patients treated with hypomethylating agents rather than standard induction rose from 7% to 24%. 6 The earliest clinical data of hypomethylating therapy in patients with AML were noncomparative trials mostly involving individuals unfit for induction chemotherapy Next, subgroup analyses of large, prospective, phase 3 trials of Aza or Dec demonstrated superior outcomes for hypomethylating therapy over best supportive care in patients with low blast count (20%-30%) AML. 25,32,33 For example, in the AZA-001 trial, elderly unfit patients with 20%-30% BM blasts who were randomized to Aza therapy experienced significantly prolonged overall survival (24.5 months) compared with those receiving conventional care regimens (16 months; p.005). 25 Recent studies suggest that, although hypomethylating therapy in AML patients results in lower CR rates (10%-20%) than conventional intensive chemotherapy, an additional 10%-30% of these individuals nevertheless exhibit evidence of some disease response or stabilization and have overall survival rates equivalent or superior to other conventional treatments. 13,26,34 Lastly, and perhaps most importantly, hypomethylating therapy was well tolerated over long periods of time in unfit elderly individuals, with fewer required hospital days and RBC and platelet transfusions. 35,36 To date, the question of which older patients with AML benefit from intensive versus hypomethylating therapy has been addressed only in retrospective analyses. Quintas-Cardama et al reviewed the outcomes of 671 older patients with AML treated with upfront intensive induction therapy or Aza or Dec-based therapy at MD Anderson Cancer Center. 13 Although CR rates were significantly higher after intensive versus epigenetic chemotherapy (42% vs 28%; p.001), there was no difference in 8-week early death (18% vs 11%; p.075), 2-year relapse-free survival (28% vs 39%; p.84), or median overall survival (6.7 vs 6.5 months; p.413) rates. In addition, there was no survival advantage for either induction strategy in AML patients 70 years old or those with intermediate-risk karyotype AML, adverse-risk karyotype AML, Eastern Cooperative Oncology Group (ECOG) performance status, renal insufficiency, or FLT-3 ITD mutations. Only patients with NPM-1 mutated AML benefited from intensive induction. Almost half of the intensively treated patients in this study received high-dose cytarabine and idarubicin (as opposed to more standard dose infusional cytarabine and daunorubicin) induction, and the majority of patients treated with hypomethylating agents also received other investigational agents. 13 For this reason, we recently analyzed our own experience with intensive 7 3 -based chemotherapy versus Dec or Aza treatment in 167 consecutive unselected AML patients 60 years of age at Roswell Park Cancer Institute. 34 Similarly to Quintas-Cardama, 13 we found that standard intensive chemotherapy resulted in 2-fold higher CR rates than hypomethylating therapy (43% vs 20%; p.01). Although univariate analysis demonstrated longer overall survival after intensive versus hypomethylating therapy (10.7 vs 9.1 months; p.01), multivariate analysis highlighted no independent impact of treatment choice. Subgroup analysis demonstrated similar outcomes after intensive versus Aza or Dec therapy in older patients with adverse karyotype, secondary, or FLT-3-mutated AML. 34 Investigators from the Netherlands analyzed their center s results in 227 AML patients 60 years old consecutively treated with intensive chemotherapy (n 90), Aza (n 26), or best supportive care (n 97). Despite the relatively small number of Aza-treated patients in this study, van der Helm et al also found similar overall 1-year (57% vs 56%, p.93) and 2-year (35% vs 35%, p.92) survival rates after intensive versus Aza therapy. Both induction modalities were significantly superior to supportive care only (1- and 2-year overall survival of 16% and 2%, respectively). 36 Based on these results suggesting the equivalency of these upfront treatment approaches in prolonging overall survival, epigenetic therapy now has an established role in the upfront treatment of elderly individuals with AML. There are ongoing efforts to identify biological subsets of AML most likely to respond to hypomethylating therapy. Blum et al demonstrated a very high overall response rate of 75% (50% CR in 8 of 16 patients and 4 incomplete CR) after 10-day Dec therapy in complex karyotype AML patients and reported a response rate of 91% (10 of 11 patients) in patients with AML characterized by monosomy 7 or del(7q) abnormalities. 27 Other groups have also 16 American Society of Hematology

4 reported CR rates of 33%-47% after hypomethylating therapy in patients with unfavorable karyotype AML or AML characterized by chromosome 5 and/or 7 aberrations. 30,35,37,38 However, most of these studies involved very small numbers of treated patients (n 20). Moreover, despite these impressive CR rates, other retrospective analyses have demonstrated no significant overall survival benefit to Dec or Aza therapy compared with intensive chemotherapy in AML with adverse cytogenetics or chromosome 5 and 7 abnormalities. 13,34,36,38 In an intriguing study, Metzeler et al reported a CR rate of 75% after Dec therapy in 8 patients with AML characterized by DNMT3A mutations. 39 However, in a larger study of 68 older patients with AML, Dinardo et al found no direct correlation between DNMT3A, IDH1,orIDH2 mutational status with response, event-free, or overall survival after upfront epigenetic therapy. 40 However, this study was limited by its retrospective nature and the treatment with other agents in addition to hypomethylating agents, which may have affected responses. 40 Further studies clarifying those biological factors predictive of response to hypomethylating therapy in this patient population are eagerly awaited. Emerging data have suggested that, of the 2 hypomethylating agents, Dec may represent the more effective agent for treatment of AML in older patients. 13 In a multicenter phase 3 trial, Kantarjian et al demonstrated superior response rates for 5-day Dec therapy compared with LDAC (20 mg/m 2 once daily) in unfit elderly patients with AML. Post hoc analysis of this trial subsequently demonstrated a trend to overall survival favoring Dec. 26,41 These data led to the approval of Dec for the treatment of high-blast-count AML in Europe. However, these same results were cited as the reason for the rejection of Dec for the same treatment indication in the United States. One large retrospective analysis found a statistically significant improvement in overall survival for Dec over Aza in elderly patients with AML. 13 Currently, the hypomethylating regimen associated with the highest response rates in older AML appears to be a 10-day regimen of Dec dosed at 20 mg/m 2 daily. As opposed to 3- or 5-day Dec regimens, this 10-day treatment has been shown to consistently result in CR rates of 31%-47% and overall median survival durations of 9-12 months. 27,35,37 The caveat is that this treatment can be associated with significant myelosuppression, and many patients require inpatient hospitalization for at least the first cycle of therapy and potentially for several weeks afterward for daily transfusions and infectious complications. Ten-day Dec induction has also been associated with treatment mortality rates indistinguishable from those of intensive chemotherapy in elderly individuals. 13,34 For these reasons, unfit older individuals desiring largely outpatient therapy and for whom treatment-related mortality is a concern may be considered for subcutaneous Aza, 5-day Dec, or LDAC therapy as an alternative to 10-day Dec induction. Novel agents for older AML patients Despite advances in our understanding of and options for the treatment of elderly AML over the last few years, the median survival times of almost all of the standard treatment approaches (with the exception of allogeneic stem cell transplantation) in this patient population remain 12 months. Clearly, there is a need for newer more effective and less toxic therapies for older AML patients. Unfortunately, it is estimated that only 5%-10% of adult AML patients enroll in clinical trials nationwide, 16 making it difficult to impossible to determine which agents are superior to the currently available options in a timely fashion. Moreover, to date, many agents in recent clinical development for this patient population have turned out to be either too toxic in older individuals or ineffective in improving overall survival for elderly patients with adverse prognostic features (ie, secondary AML, unfavorable cytogenetics, poor performance status). A complete discussion of experimental therapies currently available for older AML patients is beyond the scope of this article. The reader is referred to recent reviews for additional information At present, the only investigational therapeutic approach of note for upfront consideration in older patients with AML is targeted FLT-3 kinase inhibitor therapy for FLT-3 ITD-mutant AML. In contrast to younger patients, FLT-3 ITD mutations appear to have a negative impact on the outcome of patients years of age with primary cytogenetically normal AML treated with intensive chemotherapy. 45 The significance of FLT-3 mutations alone in other older individuals with AML is less clear. 15,45 However, given the proliferative advantage conferred on AML cells with constitutive FLT-3 kinase activation and the relative chemoresistance of this disease, the use of oral receptor tyrosine kinases specifically targeted against this signaling pathway is an attractive option for the treatment of unfit older patients with FLT-3 mutant disease. Prior studies have also shown that epigenetic therapy results in similar (poor) outcomes as intensive chemotherapy in older patients with FLT-3 mutant AML. 13,34 Clinical trials of successive FLT-3 inhibitors as monotherapy for patients with relapsed/refractory FLT-3 mutant AML patients demonstrated transient reductions in peripheral blasts in some patients, as well as CRs and prolonged survival. 42,46 The addition of sorafenib, an oral inhibitor of multiple tyrosine kinases including FLT-3, to upfront intensive chemotherapy was neither well tolerated nor beneficial in unselected older patients with AML. 47 However, a phase 2 trial of sorafenib and Aza therapy in patients with newly diagnosed and relapsed/refractory FLT-3 mutant AML (median age of 64 years) was well tolerated and resulted in an overall response rate of 46%. 48 Based on these results, older individuals with FLT-3 mutant AML should ideally be considered for therapy incorporating a FLT-3 inhibitor as a part of the overall treatment regimen. Postremission therapy for older AML patients The best therapeutic option for older patients with AML after achievement of CR with upfront therapy remains uncertain. Individuals up to the age of 75 years who achieve sufficient disease control after upfront AML therapy and have few comorbidities should be considered for consolidation with allogeneic stem cell transplantation (allosct), ideally with reduced intensity conditioning regimens, because this remains the only potential curative therapeutic option for these patients. Analyses of the SEER database clearly show that older individuals (46 of 5480 patients or 0.8%) who received allosct for AML therapy had the longest overall survival after diagnosis (22 vs 6 months after AML treatment alone and 3 months for the entire cohort). Two-year survival rates after AML diagnosis in allosct recipients aged and years were also surprisingly high, at 50% and 30.5%, respectively. 6 As expected, the presence of concomitant comorbidities, lack of an appropriate donor, and other financial and psychosocial issues (specifically the lack of an adequate caregiver for many elderly individuals) may preclude allosct in the majority of older patients. In a separate chapter, Dr. Sorror discusses criteria for the selection of AML patients for hematopoietic stem cell transplantation. For those individuals in remission who are not eligible for allosct, the standard approach has been to administer consolidation chemotherapy consisting of lower doses of the same agents used in induction therapy. To date, there is no consensus on the number of consolidation chemotherapy cycles (range 1-4), number of agents Hematology

5 (cytarabine alone vs cytarabine anthracycline), and drug dose (high- vs intermediate-dose cytarabine) needed for the best possible outcomes for older patients with AML. In the Medical Research Council AML11 trial, 1314 older patients with AML who achieved remission after 2 cycles of standard induction were prospectively randomized to receive 1 additional chemotherapy course (total 3 courses) or an additional 3 courses after remission (total 6 courses). Long-term outcomes did not differ between patients treated with 3 versus 6 cycles, suggesting the lack of any benefit beyond 1 cycle of consolidation therapy. 49 Although numerous other studies have examined a variety of other consolidation approaches in elderly AML patients, all of these have consistently reported median disease-free survival durations of 1 year (range months) and high recurrence rates (60%-100%; for review, see Wedding et al 2 ). For lack of better information, older patients with favorable- or intermediate-risk AML who achieve CR after upfront cytarabine and anthracycline-based chemotherapy typically are offered 2-4 cycles of intermediate- to high-dose cytarabine. In contrast, patients with adverse karyotype AML who achieve CR have been shown to fare poorly regardless of intensive induction and consolidation chemotherapy and therefore should be referred for investigational therapy in the postremission setting. 50 Older patients receiving upfront therapy with Dec or Aza will require a median of 2-4 cycles of therapy to achieve best response. Despite lower morphologic CR rates compared with intensive chemotherapy, many older patients with AML achieve adequate disease control and prolonged survival with hypomethylating therapy and are therefore recommended to continue on therapy indefinitely until evidence of disease progression, mirroring the treatment approach in myelodysplastic syndrome patients. 35 Dec or Aza therapy has also been used as consolidation or maintenance therapy in older patients with AML in CR and, retrospectively at least, has been shown to prolong overall disease-free survival in some individuals. 51 Communicating treatment outcomes to older AML patients Older individuals with AML who are deemed ineligible or unsuitable for allosct should be counseled early in the course of the disease about their overall prognosis, specifically the fact that, although current and investigational treatment approaches may extend survival, they will not be curative. Surveys of newly diagnosed patients with AML have demonstrated that the majority of individuals do not recall being offered more than one treatment option and grossly overestimate their long-term prognosis and chance for cure, although the treating physicians clearly documented discussion of these issues in the patients medical charts. 19,52 A mutual understanding between the patient, his/her family members, and the treating oncologist early in the treatment process that the disease will eventually be life-ending may make it easier to hold subsequent conversations on topics such as health care proxies, do not resuscitate/do not intubate directives, and end-of-life care when the time comes. Proposed therapeutic approach A proposed approach to the older adult with AML is provided in Figure 1. In general, individuals without life-threatening organ failure or hyperleukocytosis may safely delay therapy to allow for geriatric assessment and cytogenetic/ molecular characterization of their disease. Given median survival durations of 12 months with currently available agents, all older adults with AML should be Figure 1. Potential treatment approach for the older adult with AML. encouraged, whenever possible, to participate in clinical trials addressing the unmet therapeutic needs of this patient population. In the absence of appropriate trials, fit older individuals with favorable karyotype AML or NPM-1-mutated disease (without FLT-3 mutation) should be offered intensive chemotherapy with a cytarabineand anthracycline-based regimen followed by 2-4 cycles of consolidation chemotherapy. Fit older patients with intermediate-risk AML may be offered upfront intensive chemotherapy or hypomethylating therapy. Individuals with AML with adverse karyotype and unfit older patients with AML (regardless of karyotype) are unlikely to benefit from intensive induction or consolidation chemotherapy and therefore should be treated preferentially with hypomethylating agents or investigational therapies. Fit patients with intermediate- or poor-risk AML who achieve CR should be referred for allosct, preferably with reduced-intensity conditioning. Other patients in CR may be treated with consolidation chemotherapy (intermediate karyotype AML), hypomethylating therapy (adverse karyotype), or investigational agents. Any patients with relapsed/refractory AML should be strongly encouraged to pursue experimental therapy. Those patients with FLT-3-mutated AML should be considered for therapeutic regimens incorporating FLT-3 inhibitors in the upfront or relapsed setting. It is important to keep in mind that AML will be a life-ending disease for the majority of these patients. It is therefore essential to involve older adults in therapeutic decision-making process at diagnosis and throughout their disease course because the selection of the appropriate aggressiveness of therapy for many individuals may be based more on their personal treatment goals than a defined therapeutic algorithm. Conclusions In the current era, the majority of older patients with AML should be offered definitive antileukemic therapy to prolong both quantity and 18 American Society of Hematology

6 quality of life remaining. Performance status, comorbidities, disease biology, QOL, and long-term treatment goals should all be considered in the selection of the most appropriate therapeutic approach for each patient. Acknowledgments The author is supported in whole or in part by funding from the Cancer Clinical Investigator Team Leadership Award awarded by the National Cancer Institute through a supplement to Grant P30CA Disclosures Conflict-of-interest disclosure: The author has been affiliated with the speakers bureau for Incyte and was on an advisory board for Immunogen. Off-label drug use: decitabine and azacytidine for high-blast-count AML. Correspondence Eunice S. Wang MD, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263; Phone: (716) ; Fax: (716) ; eunice.wang@roswellpark.org. References 1. American Cancer Society. Cancer Facts and Figures, Atlanta: American Cancer Society; Wedding U, Bokemeyer C, Meran JG, et al. Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG). Onkologie. 2004;27(1): Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27(1): Kantarjian H, O Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5): Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18): Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12): Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113(1): Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006;91(11): Kantarjian H, Ravandi F, O Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22): Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757): Malfuson JV, Etienne A, Turlure P, et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia. Haematologica. 2008;93(12): Marcucci G, Yan P, Maharry K, et al. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014;32(6): Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24): Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and micrornaexpression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4): Daver N, Liu Dumlao T, Ravandi F, et al. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013;13(4): Doria-Rose VP, Harlan LC, Stevens J, Little RF. Treatment of de novo acute myeloid leukemia in the United States: a report from the Patterns of Care program. Leuk Lymphoma. Prepublished on March 7, 2014, as DOI / Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13): Jackson K, Mollee P, Morris K, et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. Leuk Lymphoma. 2014;55(1): Sekeres MA, Stone RM, Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18(4): Alibhai SM, Leach M, Kermalli H, et al. The impact of acute myeloid leukemia and its treatment on quality of life and functional status in older adults. Crit Rev Oncol Hematol. 2007;64(1): Alibhai SM, Leach M, Gupta V, et al. Quality of life beyond 6 months after diagnosis in older adults with acute myeloid leukemia. Crit Rev Oncol Hematol. 2009;69(2): Harb AJ, Tan W, Wilding GE, et al. Treating octogenarian and nonagenarian acute myeloid leukemia patients predictive prognostic models. Cancer. 2009;115(11): Wetzler M, Mrozek K, Kohlschmidt J, et al. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 2014;99(2): Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6): Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4): Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21): Blum W, Garzon R, Klisovic RB, et al. Clinical response and mir-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107(16): Cashen AF, Schiller GJ, O Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4): Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2 deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004; 103(5): Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid Hematology

7 leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97(3): Bories P, Bertoli S, Huguet F, et al. Efficacy of frontline 5-azacytidine in older AML patients unfit for chemotherapy [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21): Becker H, Suciu S, Rüter B, et al. Low-dose decitabine vs best supportive care in older patients with AML and low blast counts: results of a subgroup analysis of the randomized phase III study of the EORTC Leukemia Cooperative Group and German MDS Study Group [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21): Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8): Gupta N, Gandhi S, Miller A, et al. Comparison of epigenetic versus intensive chemotherapy for newly diagnosed acute myeloid leukemia patients 60 years old: the Roswell Park experience [abstract]. Blood (ASH Annual Meeting Abstracts). 2013;122(21): Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymphoma. 2013;54(9): van der Helm LH, Scheepers ER, Veeger NJ, et al. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6(1): Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymphoma. 2014;55(7): Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115(24): Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5): Dinardo CD, Patel KP, Garcia-Manero G, et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014;55(8): Thomas XG, Arthur C, Delaunay J, Jones M, Berrak E, Kantarjian HM. A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014;14(1): Lancet JE. New agents: great expectations not realized. Best Pract Res Clin Haematol. 2013;26(3): Isidori A, Venditti A, Maurillo L, et al. Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. Expert Rev Hematol. 2013;6(6): Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma. 2014;55(5): Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and micrornaexpression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(18): Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29): Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31(25): Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23): Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5): Buchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24(16): Tawfik B, Sliesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1): Yogaparan T, Panju A, Minden M, Brandwein J, Mohamedali HZ, Alibhai SM. Information needs of adult patients 50 or older with newly diagnosed acute myeloid leukemia. Leuk Res. 2009;33(9): American Society of Hematology

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy

More information

N Engl J Med Volume 373(12): September 17, 2015

N Engl J Med Volume 373(12): September 17, 2015 Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most

More information

New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke

New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version

More information

Evolving Targeted Management of Acute Myeloid Leukemia

Evolving Targeted Management of Acute Myeloid Leukemia Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed

More information

Corporate Medical Policy. Policy Effective February 23, 2018

Corporate Medical Policy. Policy Effective February 23, 2018 Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia

More information

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo

More information

The Changing Face of MDS: Advances in Treatment

The Changing Face of MDS: Advances in Treatment Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor

More information

Remission induction in acute myeloid leukemia

Remission induction in acute myeloid leukemia Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein

More information

Background CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.

Background CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035. Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller

More information

AML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013

AML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006

More information

New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke

New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke University of Groningen New treatment strategies in myelodysplastic syndromes and acute myeloid leukemia van der Helm, Lidia Henrieke IMPORTANT NOTE: You are advised to consult the publisher's version

More information

Single Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia

Single Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia Single Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments

More information

All patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!

All patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast! All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University

More information

Personalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center

Personalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:

More information

Treatment of Low-Blast Count AML. Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata

Treatment of Low-Blast Count AML. Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata Treatment of Low-Blast Count AML Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata Definition of Low-Blast Count AML Blast counts 20-30%, or > 10%? v Retrospective

More information

CREDIT DESIGNATION STATEMENT

CREDIT DESIGNATION STATEMENT CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research

More information

III. AML IN OLDER ADULTS: ARE WE LISTENING?

III. AML IN OLDER ADULTS: ARE WE LISTENING? III. AML IN OLDER ADULTS: ARE WE LISTENING? Mikkael A. Sekeres, MD, MS* AML is a disease of older adults. In the US, the median age is 68 years and the age-adjusted population incidence is 17.6 per 100,000

More information

New concepts in the management of elderly patients with AML

New concepts in the management of elderly patients with AML New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute

More information

HEMATOLOGIC MALIGNANCIES BIOLOGY

HEMATOLOGIC MALIGNANCIES BIOLOGY HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION

More information

Treating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS

Treating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium azacitidine 100mg powder for suspension for injection (Vidaza ) No. (589/09) Celgene Ltd 05 March 2010 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Leukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto

Leukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et

More information

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,

More information

National Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008

National Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008 Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be

More information

Reference: NHS England 1602

Reference: NHS England 1602 Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC

More information

Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital

Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival

More information

Management of Acute Myeloid Leukemia Patients Old than 60 Years in Casablanca: A Great Challenge in Developing Countries

Management of Acute Myeloid Leukemia Patients Old than 60 Years in Casablanca: A Great Challenge in Developing Countries Cancer Research Journal 2018; 6(3): 74-78 http://www.sciencepublishinggroup.com/j/crj doi: 10.11648/j.crj.20180603.11 ISSN: 2330-8192 (Print); ISSN: 2330-8214 (Online) Management of Acute Myeloid Leukemia

More information

New and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS)

New and Emerging Strategies in the Treatment of Patients with Higher risk Myelodysplastic Syndromes (MDS) Welcome to Managing Myelodysplastic Syndromes. My name is David Steensma. I am an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Adult Leukemia Program at Dana Farber

More information

Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain

Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531

More information

Disclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:

Disclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures: Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,

More information

Acute myeloid leukemia. M. Kaźmierczak 2016

Acute myeloid leukemia. M. Kaźmierczak 2016 Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production

More information

AML Emerging Treatment Strategies

AML Emerging Treatment Strategies Welcome and Introduction Clare Karten, MS Senior Director, Mission Education The Leukemia & Lymphoma Society AML Emerging Treatment Strategies Wendy Stock, MD Professor of Medicine, Section of Hematology/Oncology

More information

How the Treatment of Acute Myeloid Leukemia is Changing in 2019

How the Treatment of Acute Myeloid Leukemia is Changing in 2019 How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City

More information

AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered

AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE

More information

Acute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg

Acute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:

More information

midostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age.

midostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age. midostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age. perc deliberated on the toxicity profile of midostaurin and noted that

More information

39% Treated. 61% Untreated. 33% UnRx. 45% UnRx. 59% UnRx. 80% UnRx

39% Treated. 61% Untreated. 33% UnRx. 45% UnRx. 59% UnRx. 80% UnRx AML in the Elderly สน น ว ส ทธ ศ กด ช ย งานประช มว ชาการกลางป สมาคมโลห ตว ทยาแห งประเทศไทย คร งท 53 25-26 ต ลาคม 2561 ณ โรงแรมเลอ เมอร เด ยน เช ยงใหม จ งหว ดเช ยงใหม 33% UnRx 45% UnRx 59% UnRx 80% UnRx

More information

Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies

Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies Sabine Kayser, * Julia Krzykalla, Michelle A. Elliott, Kelly Norsworthy, Patrick Gonzales,

More information

perc deliberated upon: a pcodr systematic review other literature in the Clinical Guidance Report providing clinical context

perc deliberated upon: a pcodr systematic review other literature in the Clinical Guidance Report providing clinical context require close monitoring. perc noted that induction therapy is generally administered in-hospital while consolidation therapy is administered on an out-patient basis. Because of the potential for serious

More information

BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib

BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid

More information

SUPPLEMENTARY APPENDIX

SUPPLEMENTARY APPENDIX SUPPLEMENTARY APPENDIX A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy Michael Lübbert, 1 Björn

More information

Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ

Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase

More information

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs

More information

Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias

Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The

More information

Emerging Treatment Options for Myelodysplastic Syndromes

Emerging Treatment Options for Myelodysplastic Syndromes Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene

More information

Systemic Treatment of Acute Myeloid Leukemia (AML)

Systemic Treatment of Acute Myeloid Leukemia (AML) Guideline 12-9 REQUIRES UPDATING A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment of Acute Myeloid Leukemia (AML) Members of the Acute Leukemia

More information

LAM 20-30% Cristina Papayannidis, MD, PhD DIMES, Istituto di Ematologia L. e A. Seràgnoli Università di Bologna

LAM 20-30% Cristina Papayannidis, MD, PhD DIMES, Istituto di Ematologia L. e A. Seràgnoli Università di Bologna LAM 20-30% Cristina Papayannidis, MD, PhD DIMES, Istituto di Ematologia L. e A. Seràgnoli Università di Bologna FAB CLASSIFICATION OF MYELODYSPLASTIC SYNDROME Subtype % Blood Myeloblasts Bone Marrow Myeloblasts

More information

Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia

Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng

More information

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo

More information

National Institute for Health and Care Excellence. Single Technology Appraisal (STA)

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Single Technology Appraisal (STA) Gemtuzumab ozogamacin for untreated de novo acute myeloid leukaemia Response to consultee and commentator comments re-scope Please note: Comments received in the course

More information

Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML)

Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Neue zielgerichtete Behandlungsoptionen der neu diagnostizierten FLT3-positiven Akuten Myeloischen Leukämie (AML) Prof. Hartmut Döhner Klinik für Innere Medizin III, Universitätsklinikum Ulm Midostaurin

More information

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Acute Myeloid Leukemia Articles Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Bruno C. Medeiros, 1 Megan Othus, 2,3 Min Fang, 3,4 Frederick R. Appelbaum,

More information

Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine

Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine Published Ahead of Print on August 8, 2012, as doi:10.3324/haematol.2012.065151. Copyright 2012 Ferrata Storti Foundation. Early Release Paper Transfusion independence and survival in patients with acute

More information

La lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara

La lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New

More information

Less Intensive Therapy For Older Aml Patients

Less Intensive Therapy For Older Aml Patients Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2013 Less Intensive Therapy For Older Aml Patients William

More information

5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA

5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana

More information

[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014

[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 [ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may

More information

Maintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status

Maintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in

More information

VYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA

VYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA VYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA Sarah Mae Rogado PharmD Candidate 2017 Preceptors: Rozena Varghese, PharmD, CMPP; Rachel Brown, PharmD MedVal Scientific Information

More information

Molecularly Targeted Therapies - Strategies of the AMLSG

Molecularly Targeted Therapies - Strategies of the AMLSG Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]

More information

Acute Myeloid Leukemia Progress at last

Acute Myeloid Leukemia Progress at last Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients

More information

Recommended Timing for Transplant Consultation

Recommended Timing for Transplant Consultation REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org

More information

Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France

Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Should lower-risk myelodysplastic syndrome patients be transplanted upfront? YES Ibrahim Yakoub-Agha France Myelodysplastic syndromes (MDS) are heterogeneous disorders that range from conditions with a

More information

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,500 108,000 1.7 M Open access books available International authors and editors Downloads Our

More information

The Past, Present, and Future of Acute Myeloid Leukemia

The Past, Present, and Future of Acute Myeloid Leukemia The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review

More information

Welcome and Introductions

Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Welcome and Introductions Information for Patients With Acute Myeloid Leukemia (AML) Mark B. Juckett, MD Vice Chair for Clinical Affairs and Quality

More information

Meet-the-Expert: AML Treating older patients with AML

Meet-the-Expert: AML Treating older patients with AML Meet-the-Expert: AML Treating older patients with AML Sergio Amadori Tor Vergata University Hospital Rome Istanbul 2012 AML in older patients Poor prognosis Minority treated with intensive Cx Treatment

More information

National Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007

National Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007 Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to

More information

Acute myeloid leukemia: a comprehensive review and 2016 update

Acute myeloid leukemia: a comprehensive review and 2016 update OPEN Citation: (2016) 6, e441; doi:10.1038/bcj.2016.50 www.nature.com/bcj REVIEW Acute myeloid leukemia: a comprehensive review and 2016 update I De Kouchkovsky 1 and M Abdul-Hay 1,2 Acute myeloid leukemia

More information

KEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant

KEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,

More information

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia Fredly et al. Clinical Epigenetics 2013, 5:13 RESEARCH Open Access The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

More information

Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference

Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor

More information

AIH, Marseille 30/09/06

AIH, Marseille 30/09/06 ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille

More information

Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome

Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome RESEARCH ARTICLE Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome AJH Mrinal M. Patnaik, 1 Emnet A. Wassie, 1 Terra L. Lasho, 2 Curtis

More information

Page: 1 of 12. Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Leukemia

Page: 1 of 12. Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Leukemia Page: 1 of 12 Last Review Status/Date: September 2015 Genetic Testing for FLT3, NPM1, and CEBPA Mutations in Acute Myeloid Description Treatment of acute myeloid leukemia (AML) is based upon risk stratification,

More information

Risk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome

Risk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %

More information

Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD

Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood

More information

Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases

Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases DOI:10.22034/APJCP.2018.19.2.421 RESEARCH ARTICLE Editorial Process: Submission:08/01/2017 Acceptance:12/09/2017 Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete

More information

Myelodysplastic Syndromes: Challenges to Improving Patient and Caregiver Satisfaction

Myelodysplastic Syndromes: Challenges to Improving Patient and Caregiver Satisfaction Supplement issue Myelodysplastic Syndromes: Challenges to Improving B. Douglas Smith, MD Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins

More information

GENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA

GENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,

More information

Belgium recommendations for the management of acute promyelocytic leukaemia

Belgium recommendations for the management of acute promyelocytic leukaemia 6 Belgium recommendations for the management of acute promyelocytic leukaemia S. Wittnebel, MD, PhD 1 The management of acute promyelocytic leukaemia has evolved considerably. The standard front-line approach

More information

Treatment of AML in biological subgroups

Treatment of AML in biological subgroups Hematology, 2005; 10 Supplement 1: 281 /285 ACUTE MYELOID LEUKEMIA Treatment of AML in biological subgroups THOMAS BUECHNER, WOLFGANG E. BERDEL, CLAUDIA SCHOCH, TORSTEN HAFERLACH, HUBERT L. SERVE, SUSANNE

More information

Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia

Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM

More information

Gilteritinib for relapsed or refractory acute myeloid

Gilteritinib for relapsed or refractory acute myeloid NIHR Innovation Observatory Evidence Briefing: May 2018 Gilteritinib for relapsed or refractory acute myeloid leukaemia (AML) with an FLT3 mutation second line NIHRIO (HSRIC) ID: 11486 NICE ID: 8749 LAY

More information

Myelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans

Myelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments

More information

Protocol. Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia

Protocol. Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia Hematopoietic Stem-Cell Transplantation for Acute Myeloid (80126) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/15 Preauthorization Yes Review Dates: 04/07, 05/08, 05/09, 05/10, 05/11,

More information

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed

MYELODYSPLASTIC SYNDROMES: A diagnosis often missed MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic

More information

Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Acute Myeloid Leukaemia

Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Acute Myeloid Leukaemia Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Acute Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary

More information

Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note

Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel

More information

CLINICAL STUDY REPORT SYNOPSIS

CLINICAL STUDY REPORT SYNOPSIS CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care

More information

Molecularly targeted therapies for acute myeloid leukemia

Molecularly targeted therapies for acute myeloid leukemia Molecularly targeted therapies for acute myeloid leukemia Eytan M. Stein 1 TREATMENT OF ACUTE MYELOID LEUKEMIA:MOVING BEYOND 3 7 1 Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

More information

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis Pathol. Oncol. Res. (2018) 24:469 475 DOI 10.1007/s12253-017-0266-7 ORIGINAL ARTICLE Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single

More information

INTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS

INTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS INTRODUCTION TO CYTOGENETICS AND MOLECULAR TESTING IN MDS Saturday, September 29, 2018 Cyrus C. Hsia, HBSc, MD, FRCPC Associate Professor of Medicine, Schulich School of Medicine and Dentistry, Western

More information

Minimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital

Minimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical

More information

Indication for unrelated allo-sct in 1st CR AML

Indication for unrelated allo-sct in 1st CR AML Indication for unrelated allo-sct in 1st CR AML It is time to say! Decision of allo-sct: factors to be considered Cytogenetic risk status Molecular genetics FLT3; NPM1, CEBPA. Response to induction Refractoriness

More information

RESEARCH ARTICLE. Introduction Wiley Periodicals, Inc.

RESEARCH ARTICLE. Introduction Wiley Periodicals, Inc. De novo acute myeloid leukemia with 20 29% blasts is less aggressive than acute myeloid leukemia with 30% blasts in older adults: a Bone Marrow Pathology Group study AJH Robert Paul Hasserjian, 1 * Federico

More information

Mayer et al. BMC Cancer 2014, 14:69

Mayer et al. BMC Cancer 2014, 14:69 Mayer et al. BMC Cancer 2014, 14:69 RESEARCH ARTICLE Open Access Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or

More information

Medical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Medical Policy. MP Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Medical Policy MP 8.01.26 BCBSA Ref. Policy: 8.01.26 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy Related Policies 2.04.124 Genetic Testing for FLT3, NPM1, and CEBPA Variants in

More information